Skip to main content

Table 1 Patients’ baseline characteristics and diagnoses at 2 years follow-up

From: Profiling of IgG antibodies targeting unmodified and corresponding citrullinated autoantigens in a multicenter national cohort of early arthritis in Germany

Variable

All (n = 411)

Test cohort (n = 329)

Validation cohort (n = 82)

p value

Mean/%

SD

Mean/%

SD

Mean/%

SD

Age

56.5

14.6

56.7

14.6

55.7

14.4

0.57

SJC28

6.1

5.4

6.3

5.4

5.4

5.3

0.14

TJC28

9.3

6.0

9.4

5.9

9.0

6.7

0.68

Duration

11.7

7.0

11.8

7.0

11.1

6.8

0.37

CDAI

25.9

12.8

26.2

12.5

24.5

14.1

0.32

CRP

21.6

31.4

21.3

32.2

22.9

28.3

0.67

DAS28

4.6

1.3

4.6

1.3

4.5

1.4

0.42

Female

62.8

 

61.1

 

69.5

 

0.16

ACPA+

29.4

 

28.6

 

32.9

 

0.44

RF+

29.4

 

28.9

 

31.7

 

0.62

RA

75.2

 

76.9

 

68.3

 

0.11

Non-RA

24.8

 

23.1

 

31.7

 

1.00

 SpoA

2.9

 

2.7

 

3.6

  

 PsoA

3.6

 

3

 

6.1

  

 PMR

0.5

 

0

 

2.4

  

 CTD

1.9

 

1.2

 

4.9

  

 uA

15.9

 

16.2

 

14.7

  
  1. Baseline characteristics and diagnoses at 2 years follow-up of the total cohort, which was randomly split into a test cohort (80%) and a validation cohort (20%). SJC28 28 joint swollen joint count, TJC28 28 joint tender joint count, Duration symptom duration in weeks [wk], CDAI clinical disease activity index, CRP C-reactive protein, ACPA+ anti-citrullinated peptide antibody positive, RF+ IgM rheumatoid factor positive, RA rheumatoid arthritis, SpoA spondyloarthritis, PsoA psoriatic arthritis (not included in SpoA category), PMR polymyalgia rheumatica, CTD connective tissue disease, uA undifferentiated arthritis. p values indicate comparison between test and validation cohorts by T test, Wilcoxon’s test, or Fisher’s exact test, as indicated